Funded with Support from

This week in the news, CMV viremia in children does not necessarily lead to CMV ocular disease, higher rates of blindness are found in poorer US counties, and many patients with irritable bowel disease have retinal drusen.

This retrospective review is the first head-to-head study of abatacept vs tocilizumab in children with childhood chronic noninfectious uveitis (CCU).

Childhood uveitis is a complex condition fraught with challenges in thorough examination, delays in diagnosis, and high ocular morbidity. It is less common than adult uveitis and accounts for 5%–10% of all uveitis seen in tertiary referral clinics.

In this presentation from the Pediatric Ophthalmology Subspecialty Day 2019, Dr. Ramesh Kekunnaya discusses cataract management in children with uveitis with an emphasis on the timing of surgery and choice of IOL and the result of long-term surgical outcomes.

Dr. Utz moderates this virtual journal club with Drs. Angele-Han, Acharya, and Sen. Articles included: 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Screening, Monitoring, and Treatment of Juvenile Idiopathic Arthritis-Associated Uveitis (Sheila T. Angeles-Han, MD, MSc), Relapse of Juvenile Idiopathic Arthritis-Associated Uveitis after Discontinuation of Immunomodulatory Therapy (Nisha Acharya MD), and The Risk of Intraocular Pressure Elevation in Pediatric Noninfectious Uveitis (H. Nida Sen, MD).

Investigators describe the use of infliximab in pediatric patients with noninfectious uveitis who failed to respond to adalimumab.

Intermediate uveitis (IU) is the subset of uveitis where the major site of inflammation is the anterior vitreous and pars plana. IU is an important diagnosis to recognize in children, who are at risk for vision loss. A shorter time period from symptom onset to diagnosis is correlated with improved visual outcomes.

Weekly case challenge